Cellectis S.A. ADR (CLLS)

$2.85 +0.11 (4.01%)
Market Cap 152.30M
Revenue (ttm) 49.22M
Net Income (ttm) -36.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -74.69%
Debt to Equity Ratio 0.76
Volume 44,800
Avg Vol 180,218
Day's Range N/A - N/A
Shares Out 55.58M
Stochastic %K 85%
Beta 3.03
Analysts Strong Sell
Price Target $5.60

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 81 69 16 00
Address:
8, rue de la Croix Jarry, Paris, France
3DBuilds
3DBuilds Sep. 9 at 9:19 PM
$DNA $CLLS $NVO
0 · Reply
mikefbi
mikefbi Sep. 9 at 3:54 PM
$CLLS
0 · Reply
mikefbi
mikefbi Aug. 29 at 8:52 PM
$CLLS Still
0 · Reply
PennyScam
PennyScam Aug. 25 at 2:53 PM
$CLLS Hi RK!
3 · Reply
mikefbi
mikefbi Aug. 19 at 8:39 PM
$CLLS
0 · Reply
rlkloehn
rlkloehn Aug. 14 at 3:48 PM
$CLLS https://www.investing.com/news/swot-analysis/cellectiss-swot-analysis-gene-thera py-firms-stock-faces-pivotal-moment-93CH-4190496
0 · Reply
mikefbi
mikefbi Aug. 13 at 1:19 PM
$CLLS Looking good
0 · Reply
DaBullRunner
DaBullRunner Aug. 13 at 9:22 AM
$INVZ 🔜 $2+ THEN 🔜$3+ THEN 🔜 $4+ 🎯 HERE IS WHY👇 $ALTS $YTRA $GBIO $CLLS let’s get it bulls
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 13 at 8:19 AM
$CLLS hot stocks
0 · Reply
rlkloehn
rlkloehn Aug. 8 at 6:44 AM
$CLLS https://www.tipranks.com/news/company-announcements/cellectis-s-a-advances-ucart123-clinical-study-in-aml-treatment
0 · Reply
Latest News on CLLS
Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 11:50 AM EDT - 5 weeks ago

Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript

Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

Aug 4, 2025, 4:30 PM EDT - 5 weeks ago

Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

Jul 28, 2025, 4:30 PM EDT - 6 weeks ago

Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025

Jun 26, 2025, 4:30 PM EDT - 2 months ago

Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025

Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025

May 21, 2025, 4:30 PM EDT - 3 months ago

Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025

Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy

May 15, 2025, 10:58 AM EDT - 4 months ago

Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy

Cellectis Reports Financial Results for the First Quarter 2025

May 12, 2025, 4:30 PM EDT - 4 months ago

Cellectis Reports Financial Results for the First Quarter 2025

Cellectis to Report First Quarter Financial Results on May 12, 2025

May 6, 2025, 4:30 PM EDT - 4 months ago

Cellectis to Report First Quarter Financial Results on May 12, 2025

Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting

Apr 28, 2025, 4:30 PM EDT - 4 months ago

Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting

Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript

Mar 14, 2025, 10:36 AM EDT - 6 months ago

Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

Mar 13, 2025, 6:07 PM EDT - 6 months ago

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

Mar 7, 2025, 4:30 PM EST - 6 months ago

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

Feb 24, 2025, 1:30 AM EST - 7 months ago

Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

Cellectis: Poised To Start Answering Questions In 2025

Dec 12, 2024, 3:08 PM EST - 9 months ago

Cellectis: Poised To Start Answering Questions In 2025

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

Dec 10, 2024, 4:30 PM EST - 9 months ago

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

Nov 5, 2024, 4:30 PM EST - 11 months ago

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 1:59 PM EST - 11 months ago

Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

Nov 4, 2024, 4:30 PM EST - 11 months ago

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Oct 30, 2024, 4:30 PM EDT - 11 months ago

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

Oct 22, 2024, 2:00 AM EDT - 11 months ago

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

Sep 3, 2024, 4:30 PM EDT - 1 year ago

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Aug 30, 2024, 10:25 AM EDT - 1 year ago

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

Aug 26, 2024, 4:30 PM EDT - 1 year ago

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Aug 7, 2024, 2:00 AM EDT - 1 year ago

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Cellectis Provides Financial Results for the Second Quarter 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Cellectis Provides Financial Results for the Second Quarter 2024

FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment

Aug 1, 2024, 4:30 PM EDT - 1 year ago

FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Jul 25, 2024, 4:30 PM EDT - 1 year ago

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Jun 28, 2024, 4:30 PM EDT - 1 year ago

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Jun 20, 2024, 4:30 PM EDT - 1 year ago

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Jun 12, 2024, 4:30 PM EDT - 1 year ago

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Jun 4, 2024, 4:30 PM EDT - 1 year ago

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

May 30, 2024, 2:06 PM EDT - 1 year ago

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

May 30, 2024, 9:14 AM EDT - 1 year ago

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024

May 29, 2024, 4:30 PM EDT - 1 year ago

Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024

Cellectis Reports Financial Results for First Quarter 2024

May 28, 2024, 4:30 PM EDT - 1 year ago

Cellectis Reports Financial Results for First Quarter 2024

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

May 27, 2024, 4:30 PM EDT - 1 year ago

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

May 6, 2024, 2:00 AM EDT - 1 year ago

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

May 2, 2024, 4:30 PM EDT - 1 year ago

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

Apr 29, 2024, 4:46 PM EDT - 1 year ago

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Apr 10, 2024, 4:30 PM EDT - 1 year ago

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Jan 16, 2024, 4:30 PM EST - 1 year ago

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Dec 22, 2023, 4:30 PM EST - 1 year ago

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Cellectis' Shareholders Meeting to be Held on December 22, 2023

Nov 17, 2023, 4:30 PM EST - 1 year ago

Cellectis' Shareholders Meeting to be Held on December 22, 2023

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Nov 15, 2023, 2:30 AM EST - 1 year ago

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 2:22 PM EST - 2 years ago

Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects

Nov 3, 2023, 6:57 PM EDT - 2 years ago

Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

3DBuilds
3DBuilds Sep. 9 at 9:19 PM
$DNA $CLLS $NVO
0 · Reply
mikefbi
mikefbi Sep. 9 at 3:54 PM
$CLLS
0 · Reply
mikefbi
mikefbi Aug. 29 at 8:52 PM
$CLLS Still
0 · Reply
PennyScam
PennyScam Aug. 25 at 2:53 PM
$CLLS Hi RK!
3 · Reply
mikefbi
mikefbi Aug. 19 at 8:39 PM
$CLLS
0 · Reply
rlkloehn
rlkloehn Aug. 14 at 3:48 PM
$CLLS https://www.investing.com/news/swot-analysis/cellectiss-swot-analysis-gene-thera py-firms-stock-faces-pivotal-moment-93CH-4190496
0 · Reply
mikefbi
mikefbi Aug. 13 at 1:19 PM
$CLLS Looking good
0 · Reply
DaBullRunner
DaBullRunner Aug. 13 at 9:22 AM
$INVZ 🔜 $2+ THEN 🔜$3+ THEN 🔜 $4+ 🎯 HERE IS WHY👇 $ALTS $YTRA $GBIO $CLLS let’s get it bulls
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 13 at 8:19 AM
$CLLS hot stocks
0 · Reply
rlkloehn
rlkloehn Aug. 8 at 6:44 AM
$CLLS https://www.tipranks.com/news/company-announcements/cellectis-s-a-advances-ucart123-clinical-study-in-aml-treatment
0 · Reply
DM0n3y
DM0n3y Aug. 8 at 1:10 AM
$CLLS Who is working overtime on this one? Big spike AH
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 6 at 9:52 AM
$CLLS gappers today $ALAB $HYPF $CYRX
1 · Reply
rlkloehn
rlkloehn Aug. 5 at 1:53 AM
$CLLS The end-of-phase 1 meetings with the FDA and the EMA regarding UCART22 took place in July 2025; the launch of pivotal phase 2 is scheduled for the second half of 2025
0 · Reply
rlkloehn
rlkloehn Aug. 4 at 11:22 PM
$CLLS Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025 Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 eti-cel (UCART20x22): Phase 1 study in r/r NHL ongoing with readout expected in late 2025 Conference call and webcast scheduled for tomorrow, August 5, 2025 at 8:00AM ET / 2:00PM CET
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Aug. 4 at 7:35 PM
$CLLS
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 4 at 10:43 AM
$CLLS gappers today
0 · Reply
Manny2284
Manny2284 Aug. 3 at 6:52 PM
$BTOG $CLLS $SMX
1 · Reply
StockScanners
StockScanners Aug. 2 at 9:22 PM
$CLLS keep watch if this holds above 2.75
0 · Reply
GhostInside
GhostInside Aug. 2 at 8:33 AM
$CLLS OPA soon; 5/10B market cap would be fair
1 · Reply
Starwarsjedi
Starwarsjedi Aug. 2 at 7:58 AM
$CLLS why the run up
0 · Reply
mikefbi
mikefbi Aug. 1 at 10:54 PM
$CLLS Great Run Up over 100%
0 · Reply
PharmaExpert
PharmaExpert Aug. 1 at 6:37 PM
$AKBA, $FDMT, $CLLS, $CRDF, $ABVC 🔥🔥🔥🔥🔥
1 · Reply